Skip to main content

Patient Representatives Committee

The patient voice in clinical trial research

Canadian Cancer Trials Group (CCTG) recognizes the value and importance of engaging patients, including the patient voice in all aspects of the clinical trial life-cycle. Integrating the patient perspective into the CCTG’s overall strategic agenda ensures the research agenda has the greatest impact on cancer patients in Canada and around the world.

CCTG has implemented a model of dedicated public and patient involvement by including the Patient Representative, who are patient volunteers recruited to disease site committees similar to academic committee members with a three year extendable term.

  • The role of the CCTG Patient Representative has evolved to integrate the patient perspective into many steps of the research process with the aim of:
    • research questions that matter to patients, and
    • improved accrual
  • CCTG is committed to implementing best practices and materials to foster and facilitate patient engagement

If you are looking for more information about the CCTG Patient Representative Committee please contact Yvonne Murray, Patient Engagement Lead for information.

CCTG is currently looking for volunteers for these roles on the Patient Rep Committee:

For more information about current committee openings please contact Nancy Dusharm.

CCTG Patient Representatives Committee

IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Results from a new study show improved survival for patients with pleural mesothelioma

Late-breaking results for the IND.227 trial were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The Phase III international study evaluated the use of the immunotherapy drug pembrolizumab combined with platinum-pemetrexed chemotherapy as a first-line treatment for pleural mesothelioma patients.

More >>

CCTG Recruiting for a Patient Representative Volunteer Role

CCTG is currently seeking applications for a Patient Representative for the Hematology Disease Site Committee

More >>
 LUMOS2 international trial

CCTG brain cancer trial awarded CCS Breakthrough Grant

Canadian Cancer Society announces details of research funding for low-survival cancers, the CCTG Breakthrough Grant Application lead by Dr Marshall Pitz, has received $ 1,549,130 over 5 years. Brain cancers that are classified as grade 2 or 3 gliomas are incurable and when they recur after treatment, the lack of effective therapies for these hard-to-treat cancers leads to very poor outcomes.

More >>

Welcome to new Patient Representative Catherine Wreford

CCTG would like to welcome our new Patient Representative, Catherine Wreford who will be supporting the Brain Cancer Disease Site Committee. Catherine is a professional dancer and actress who was born and raised in Winnipeg, Manitoba, Canada. In 2013, a little over a month after giving birth to her second child, Catherine was diagnosed with incurable anaplastic astrocytoma (a malignant brain tumour).

More >>